



## Emergence of JAK Inhibitors in the Treatment of

## PSORIATIC ARTHRIT



INTERNATIONAL SPEAKER

DR PAUL BIRD

Conjoint Professor
University of New South Wales, Sydney, Australia

Paul Bird has over twenty years' experience in treating rheumatic disease, with particular expertise in Rheumatoid arthritis, Psoriatic arthritis and Ankylosing spondylitis. Professor Bird received his medical degree with Honours from the University of Newcastle, and he completed his physician and rheumatology training in Sydney. Pursuing research alongside clinical medicine and patient care, he completed a PhD in 2005 examining MRI in Rheumatoid arthritis, and a Graduate Diploma in MRI. He continues to undertake arthritis research with fellow Australian rheumatologists and with international colleagues. Internationally recognised as a specialist in rheumatic disease and imaging, he is the current Chair of the International Magnetic Resonance Imaging Research association and actively participates in national and international rheumatology research.



CHAIRPERSON

ASSOCIATE PROF

DR FARIZ YAHYA

Consultant Rheumatologist



SPEAKER

DR CHOW SOOK KHUAN

Consultant Rheumatologist

TIME	TOPIC	SPEAKER
19:00 – 19:03	Opening	<b>RICHARD SUN</b> SEA GM, Abbvie
19:03 – 19:05	Welcome Address	ASSOC. PROF. DR FARIZ YAHYA Consultant Rheumatologist
19:05 – 19:08	Opening Video	
19:08 – 19:28	Unmet Needs of Psoriatic Arthritis & role of JAK-STAT pathway in SpA treatment landscape	<b>DR CHOW SOOK KHUAN</b> Consultant Rheumatologist
19:28 – 19:58	Achieving More in The Treatment of PsA	<b>DR PAUL BIRD</b> Conjoint Professor University of New South Wales, Sydney, Australia
19:58 – 20:03	Question and Answer	
20:03 – 20:18	Navigate clinical case : SELECTing the right treatment for PsA patients in clinical setting	<b>DR PAUL BIRD</b> Conjoint Professor University of New South Wales, Sydney, Australia
20:18 – 20:28	Question and Answer	
20:28 – 20:30	Closing	ASSOC. PROF. DR FARIZ YAHYA Consultant Rheumatologist














Full prescribing information is available upon request. Please refer to full prescribing information before prescribing Adverse events should be reported to AbbVie pharmacovigilance team at drugsafety.pv@abbvie.com